BIM
TEVA icon

BlackRock Investment Management’s Teva Pharmaceuticals TEVA Stock Holding History

BlackRock Investment Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-7,500
Closed -$401K – 4120
2016
Q1 		$401K Buy
+7,500
New +$440K ﹤0.01% 2976

Other funds holding TEVA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Barrow, Hanley, Mewhinney & Strauss
Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
HCM
Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Nordea Investment Management
Nordea Investment Management Stockholm, Sweden $123B AUM 38.85% 1-Year Est. Return

BlackRock Investment Management's TEVA Position: Q4 2016 in Review

BlackRock Investment Management reduced its Teva Pharmaceuticals (TEVA) stake by 2.6% in Q4 2016, selling an estimated $2.95M and leaving 2,761,360 shares worth $100M. The position accounts for 0.12% of the portfolio, ranked #170.

BlackRock Investment Management first reported a position in TEVA in Q2 2013 and has held it in 15 quarters since. The position peaked at $274M in Q1 2015. 738 funds tracked by Wall St. Rank hold TEVA as of Q4 2016.

  • BlackRock Investment Management held 2,761,360 shares of Teva Pharmaceuticals worth $100M as of Q4 2016.
  • BlackRock Investment Management sold 73,804 Teva Pharmaceuticals shares in Q4 2016, an estimated $2.95M.
  • Teva Pharmaceuticals made up 0.12% of BlackRock Investment Management's portfolio in Q4 2016, its #170 holding.
  • BlackRock Investment Management first reported a position in Teva Pharmaceuticals in Q2 2013 and has held it in 15 quarters since.
  • BlackRock Investment Management's Teva Pharmaceuticals position peaked at $274M in Q1 2015.
  • 738 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2016.

Based on BlackRock Investment Management's 13F filing for Q4 2016, filed 10 Feb 2017.